Introduction: Management of the luteal phase in assisted reproductive technology
The increasing utilization of a gonadotropin-releasing hormone agonist ovulation trigger and the widespread use of artificial cycles for the transfer of frozen-thawed or donated embryos has renewed interest in the luteal phase in assisted reproductive technology. The "luteal phase defect"...
Gespeichert in:
Veröffentlicht in: | Fertility and sterility 2018-05, Vol.109 (5), p.747-748 |
---|---|
Hauptverfasser: | , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 748 |
---|---|
container_issue | 5 |
container_start_page | 747 |
container_title | Fertility and sterility |
container_volume | 109 |
creator | Griesinger, Georg Meldrum, David |
description | The increasing utilization of a gonadotropin-releasing hormone agonist ovulation trigger and the widespread use of artificial cycles for the transfer of frozen-thawed or donated embryos has renewed interest in the luteal phase in assisted reproductive technology. The "luteal phase defect" phenomenon is now understood as a continuum: there is less impairment with milder stimulation than with more intense ovarian stimulation, and less impairment after controlled ovarian stimulation and human chorionic gonadotropin ovulation triggering than after gonadotropin-releasing hormone agonist ovulation triggering, the latter being associated with rapid luteolysis. The intensity of the support of luteal phase necessary to achieve optimal outcomes therefore depends on the degree of luteal phase defect encountered in different treatment protocols. Ultimately, the luteal phase of an artificial cycle in which ovulation is suppressed, a corpus luteum is therefore absent, and the establishment of endometrial receptivity completely relies on the orchestrated exogenous administration of sex steroids, is the litmus test situation for the study of the efficacy of different luteal phase support preparations, doses, regimens, and routes of administration. |
doi_str_mv | 10.1016/j.fertnstert.2018.02.009 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_proquest_miscellaneous_2042230502</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2042230502</sourcerecordid><originalsourceid>FETCH-LOGICAL-p211t-e79b5d911f9529827846f908aad100400bd21bcc027ebc87e1f4f426e4e5625a3</originalsourceid><addsrcrecordid>eNo1UM9PgzAYbUyMm9N_wfToBfz6QVvqzSw6l8zoQc-kwMfGAgVpMdl_L4nz8t7l_cpjjAuIBQj1cIxrGoPzYcYYQWQxYAxgLthSSKkiqWSyYNfeHwFACY1XbIFG6yxRask-ti6MfTWVoendI3-zzu6pIxd4X_NwIN5OgWzLh4P1xBvHrffN3FXxkYaz8Yd4oPLg-rbfn27YZW1bT7dnXrGvl-fP9Wu0e99s10-7aEAhQkTaFLIyQtRGoslQZ6mqDWTWVgIgBSgqFEVZAmoqykyTqNM6RUUpSYXSJit2_5c7r_ieyIe8a3xJbWsd9ZPPEVLEBCTgLL07S6eioyofxqaz4yn_fyH5BcgqYQk</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2042230502</pqid></control><display><type>article</type><title>Introduction: Management of the luteal phase in assisted reproductive technology</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals Complete</source><source>Alma/SFX Local Collection</source><source>EZB Electronic Journals Library</source><creator>Griesinger, Georg ; Meldrum, David</creator><creatorcontrib>Griesinger, Georg ; Meldrum, David</creatorcontrib><description>The increasing utilization of a gonadotropin-releasing hormone agonist ovulation trigger and the widespread use of artificial cycles for the transfer of frozen-thawed or donated embryos has renewed interest in the luteal phase in assisted reproductive technology. The "luteal phase defect" phenomenon is now understood as a continuum: there is less impairment with milder stimulation than with more intense ovarian stimulation, and less impairment after controlled ovarian stimulation and human chorionic gonadotropin ovulation triggering than after gonadotropin-releasing hormone agonist ovulation triggering, the latter being associated with rapid luteolysis. The intensity of the support of luteal phase necessary to achieve optimal outcomes therefore depends on the degree of luteal phase defect encountered in different treatment protocols. Ultimately, the luteal phase of an artificial cycle in which ovulation is suppressed, a corpus luteum is therefore absent, and the establishment of endometrial receptivity completely relies on the orchestrated exogenous administration of sex steroids, is the litmus test situation for the study of the efficacy of different luteal phase support preparations, doses, regimens, and routes of administration.</description><identifier>EISSN: 1556-5653</identifier><identifier>DOI: 10.1016/j.fertnstert.2018.02.009</identifier><identifier>PMID: 29778366</identifier><language>eng</language><publisher>United States</publisher><subject>Female ; Gonadotropin-Releasing Hormone - agonists ; Gonadotropin-Releasing Hormone - metabolism ; Humans ; Infertility, Female - metabolism ; Infertility, Female - therapy ; Luteal Phase - drug effects ; Luteal Phase - metabolism ; Ovulation Induction - methods ; Ovulation Induction - trends ; Reproductive Techniques, Assisted - trends</subject><ispartof>Fertility and sterility, 2018-05, Vol.109 (5), p.747-748</ispartof><rights>Copyright © 2018 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,777,781,27905,27906</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/29778366$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Griesinger, Georg</creatorcontrib><creatorcontrib>Meldrum, David</creatorcontrib><title>Introduction: Management of the luteal phase in assisted reproductive technology</title><title>Fertility and sterility</title><addtitle>Fertil Steril</addtitle><description>The increasing utilization of a gonadotropin-releasing hormone agonist ovulation trigger and the widespread use of artificial cycles for the transfer of frozen-thawed or donated embryos has renewed interest in the luteal phase in assisted reproductive technology. The "luteal phase defect" phenomenon is now understood as a continuum: there is less impairment with milder stimulation than with more intense ovarian stimulation, and less impairment after controlled ovarian stimulation and human chorionic gonadotropin ovulation triggering than after gonadotropin-releasing hormone agonist ovulation triggering, the latter being associated with rapid luteolysis. The intensity of the support of luteal phase necessary to achieve optimal outcomes therefore depends on the degree of luteal phase defect encountered in different treatment protocols. Ultimately, the luteal phase of an artificial cycle in which ovulation is suppressed, a corpus luteum is therefore absent, and the establishment of endometrial receptivity completely relies on the orchestrated exogenous administration of sex steroids, is the litmus test situation for the study of the efficacy of different luteal phase support preparations, doses, regimens, and routes of administration.</description><subject>Female</subject><subject>Gonadotropin-Releasing Hormone - agonists</subject><subject>Gonadotropin-Releasing Hormone - metabolism</subject><subject>Humans</subject><subject>Infertility, Female - metabolism</subject><subject>Infertility, Female - therapy</subject><subject>Luteal Phase - drug effects</subject><subject>Luteal Phase - metabolism</subject><subject>Ovulation Induction - methods</subject><subject>Ovulation Induction - trends</subject><subject>Reproductive Techniques, Assisted - trends</subject><issn>1556-5653</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2018</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo1UM9PgzAYbUyMm9N_wfToBfz6QVvqzSw6l8zoQc-kwMfGAgVpMdl_L4nz8t7l_cpjjAuIBQj1cIxrGoPzYcYYQWQxYAxgLthSSKkiqWSyYNfeHwFACY1XbIFG6yxRask-ti6MfTWVoendI3-zzu6pIxd4X_NwIN5OgWzLh4P1xBvHrffN3FXxkYaz8Yd4oPLg-rbfn27YZW1bT7dnXrGvl-fP9Wu0e99s10-7aEAhQkTaFLIyQtRGoslQZ6mqDWTWVgIgBSgqFEVZAmoqykyTqNM6RUUpSYXSJit2_5c7r_ieyIe8a3xJbWsd9ZPPEVLEBCTgLL07S6eioyofxqaz4yn_fyH5BcgqYQk</recordid><startdate>201805</startdate><enddate>201805</enddate><creator>Griesinger, Georg</creator><creator>Meldrum, David</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>7X8</scope></search><sort><creationdate>201805</creationdate><title>Introduction: Management of the luteal phase in assisted reproductive technology</title><author>Griesinger, Georg ; Meldrum, David</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-p211t-e79b5d911f9529827846f908aad100400bd21bcc027ebc87e1f4f426e4e5625a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2018</creationdate><topic>Female</topic><topic>Gonadotropin-Releasing Hormone - agonists</topic><topic>Gonadotropin-Releasing Hormone - metabolism</topic><topic>Humans</topic><topic>Infertility, Female - metabolism</topic><topic>Infertility, Female - therapy</topic><topic>Luteal Phase - drug effects</topic><topic>Luteal Phase - metabolism</topic><topic>Ovulation Induction - methods</topic><topic>Ovulation Induction - trends</topic><topic>Reproductive Techniques, Assisted - trends</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Griesinger, Georg</creatorcontrib><creatorcontrib>Meldrum, David</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>MEDLINE - Academic</collection><jtitle>Fertility and sterility</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Griesinger, Georg</au><au>Meldrum, David</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Introduction: Management of the luteal phase in assisted reproductive technology</atitle><jtitle>Fertility and sterility</jtitle><addtitle>Fertil Steril</addtitle><date>2018-05</date><risdate>2018</risdate><volume>109</volume><issue>5</issue><spage>747</spage><epage>748</epage><pages>747-748</pages><eissn>1556-5653</eissn><abstract>The increasing utilization of a gonadotropin-releasing hormone agonist ovulation trigger and the widespread use of artificial cycles for the transfer of frozen-thawed or donated embryos has renewed interest in the luteal phase in assisted reproductive technology. The "luteal phase defect" phenomenon is now understood as a continuum: there is less impairment with milder stimulation than with more intense ovarian stimulation, and less impairment after controlled ovarian stimulation and human chorionic gonadotropin ovulation triggering than after gonadotropin-releasing hormone agonist ovulation triggering, the latter being associated with rapid luteolysis. The intensity of the support of luteal phase necessary to achieve optimal outcomes therefore depends on the degree of luteal phase defect encountered in different treatment protocols. Ultimately, the luteal phase of an artificial cycle in which ovulation is suppressed, a corpus luteum is therefore absent, and the establishment of endometrial receptivity completely relies on the orchestrated exogenous administration of sex steroids, is the litmus test situation for the study of the efficacy of different luteal phase support preparations, doses, regimens, and routes of administration.</abstract><cop>United States</cop><pmid>29778366</pmid><doi>10.1016/j.fertnstert.2018.02.009</doi><tpages>2</tpages></addata></record> |
fulltext | fulltext |
identifier | EISSN: 1556-5653 |
ispartof | Fertility and sterility, 2018-05, Vol.109 (5), p.747-748 |
issn | 1556-5653 |
language | eng |
recordid | cdi_proquest_miscellaneous_2042230502 |
source | MEDLINE; Elsevier ScienceDirect Journals Complete; Alma/SFX Local Collection; EZB Electronic Journals Library |
subjects | Female Gonadotropin-Releasing Hormone - agonists Gonadotropin-Releasing Hormone - metabolism Humans Infertility, Female - metabolism Infertility, Female - therapy Luteal Phase - drug effects Luteal Phase - metabolism Ovulation Induction - methods Ovulation Induction - trends Reproductive Techniques, Assisted - trends |
title | Introduction: Management of the luteal phase in assisted reproductive technology |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-17T17%3A44%3A43IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Introduction:%20Management%20of%20the%20luteal%20phase%20in%20assisted%20reproductive%20technology&rft.jtitle=Fertility%20and%20sterility&rft.au=Griesinger,%20Georg&rft.date=2018-05&rft.volume=109&rft.issue=5&rft.spage=747&rft.epage=748&rft.pages=747-748&rft.eissn=1556-5653&rft_id=info:doi/10.1016/j.fertnstert.2018.02.009&rft_dat=%3Cproquest_pubme%3E2042230502%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2042230502&rft_id=info:pmid/29778366&rfr_iscdi=true |